 |
| Sputnik V Corona 19 vaccine developed by Russia. © Reuters = News 1 |
Russia’s vaccine, which had been devalued amid the supply and demand for a new coronavirus infection (Corona 19) vaccine, has repeatedly reversed, and attention is also being paid to the state of vaccine development in China, a vaccine developing country in Northeast Asia.
Russia’s vaccine’Sputnik V’has been undervalued. This is because the development period was short and the development process including clinical trials was not well known, so there were many doubts about the effectiveness or safety.
However, Bloomberg News reported on the 7th (local time) that the mood changed sharply when the results of peer evaluation of the Sputnik V vaccine were published in the international medical journal Lancet. As a result of analyzing 20,000 subjects participating in the clinical trial, the effect was 91.6%.
Although it is as effective as vaccines in the US and Europe, at least 20 countries are currently preparing to enter the European market after approval of the use of the vaccine by Rush as it has added advantages such as low price and refrigerated storage.
 |
| COVID-19 vaccine produced by Sinobac-SCMP capture |
Vaccines currently in development or in clinical trials in China are Sinobag and Sinopharm, CanSino Biologics, Anhui Zhifei Longcom Biopharmaceutical and Chongqing Zhifei Biological Products. And 5 companies.
According to the China Global Times, the China Drug Administration (NMPA) conditionally approved the application for the use of the Synovac vaccine on the 5th. Synovac received an emergency use approval from the Chinese government in June last year, and since July, more than 2,200 high-risk corona19 patients, including medical staff, airport and quarantine workers, have been vaccinated.
Since July of last year, Synovac has conducted a third clinical trial in South America, Brazil, Chile, Indonesia and Turkey. In Turkey and Indonesia, 91% and 65.3% were found to have preventive effects, respectively. However, in Brazil, the efficacy of clinical trials was 50.65%, only exceeding 50% of the minimum standard for approval of use recommended by the World Health Organization (WHO).
Sinoparm received conditional approval from the authorities on December 31st. According to Hwangu Times and the like, Sinoparm said that the vaccine effect was 79.34% as a result of its phase 3 clinical trial. According to the People’s Network of China, Sinoparm will deliver 100,000 doses of the vaccine to Macau on the 7th and will be vaccinated next week.
Kanshinobilogics, a Chinese biotechnology company, developed a Corona 19 vaccine in cooperation with the Beijing Life Science Research Institute under the Chinese Military Medical Academy, and received limited approval to inoculate the Chinese military.
According to the Chinese media The Paper, Kansinobilogics has been analyzing the results of phase 3 clinical trials in Saudi Arabia, Pakistan, and Russia since the 1st, reaching safety standards and no serious side effects. On the 7th, Xinhua Network reported that Kansinobi Logics provided vaccines to the Pakistani and Cambodian military.
The Corona 19 vaccine developed by Chongqing Zipei Bio Products is currently undergoing Phase 3 for 29,000 people worldwide, and Anhui Zipei is also in the phase 3 clinical trial of the Corona 19 vaccine and is producing the product.